Am not concerned about escrow releases, you don't get into this...

Am not concerned about escrow releases, you don't get into this kind of thing early enough to be escrowed to tip them all out for chump change, also not concerned about sales at this stage, you can't rush sales of a new replacement medical device, I hope they take their time and get the early sales done right, the early adopters will be the reference points for the wider roll-out, it is imperative that they have good experiences.



The US market at the moment is 120,000 units pa, or 10,000 u/m.

This means 2,000 u/m, or 6,000 u/quarter for 20% mkt share.

Dodson says success looks like many hundreds, to possibly thousands per quarter late in CY17, if they hit these numbers and if this sort of growth continues, then 20% run rate will be achieveable by mid CY18

The upside for the company is in three main areas:

1 - execute on current plans to build market share in the US
2 - current US market expands from 120,000 units pa to 350,000 units pa (the US$800m addressable market they talk about) due to growth and mandated doctor discussion of reconstruction options with patients
3 - international, select EU and Asia markets

None of this goes away if they miss a sales target